Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology,
Tevogen shares are rising Monday after the company secured up to $50 million of financing from an existing investor aimed at supporting continued research and development efforts for Tevogen's TVGN 489.